The Louisiana emergency rule announced in October 2026 names mitragynine pseudoindoxyl, MGM-15, and MGM-16. Those names matter. Mitragynine, 7-hydroxymitragynine, and mitragynine pseudoindoxyl are not interchangeable terms, and a general reference to “kratom-related substances” does not identify the scope of the rule.
The Louisiana Department of Health announced the action on October 19, 2026. Its published emergency rule, LAC 46:LIII.2704, supplies the controlling chemical descriptions. This guide explains that document and the separate federal proceedings as of October 20, 2026.
The three substances named in Louisiana’s rule
Scroll horizontally to see all columns. Use the arrow keys when the table is focused.
| Listed substance | Names a reader may encounter | Where it appears |
|---|---|---|
| Mitragynine pseudoindoxyl | Also abbreviated MGPI in the federal proceeding. It is a different compound from mitragynine. | Section 2704(A)(1) |
| MGM-15 | Dihydro-7-hydroxymitragynine. | Section 2704(A)(2) |
| MGM-16 | 9-fluoro-dihydro-7-hydroxymitragynine; also described as 10-fluoro-dihydro-7-hydroxymitragynine under a different numbering convention. | Section 2704(A)(3) |
The table uses the common names given in the state rule. The full chemical descriptions remain important when a laboratory, regulator, or court must identify a substance. Section 2704(B) expressly covers the listed structures regardless of differences in the numbering of atomic positions. A different chemical label does not necessarily mean a different substance.
What “any quantity” means in this particular rule
Section 2704(A) adds the listed substances to Schedule I, together with the specified related forms, including possible isomers, esters, ethers, and salts. It also covers materials, compounds, mixtures, or preparations containing any quantity of a listed substance. The opening language preserves specific exceptions and an exception for substances contained in an FDA-approved pharmaceutical product.
The Louisiana text does not provide the concentration thresholds discussed in the October federal proposal. A federal threshold should therefore not be read into the state rule. Nor does the FDA-approved-product exception mean that a seller’s description of a product as a “supplement,” or a claim that its ingredients are natural, supplies an exemption.
Louisiana’s announcement and the federal proceedings are separate
Scroll horizontally to see all columns. Use the arrow keys when the table is focused.
| Action | What the document establishes |
|---|---|
| Louisiana announcement — October 19, 2026 | LDH announced its emergency rule identifying the three compounds above. The announcement date should not be substituted for a verified filing or legal effective date when evaluating a particular transaction. |
| Federal temporary order — August 26, 2026 | The later DEA notice identifies an existing temporary Schedule I order covering mitragynine pseudoindoxyl, MGM-15, and MGM-16. |
| Federal notice — October 14, 2026 | DEA proposed a different threshold-based treatment of 7-hydroxymitragynine and mitragynine pseudoindoxyl. This notice of intent is not itself the replacement scheduling order. |
The October 14 Federal Register notice says a new temporary order would be published on or after November 13, 2026. It also states that the existing mitragynine pseudoindoxyl order remains in force until it expires or a replacement order is published and the previous order is withdrawn. A proposed change should not be treated as permission to disregard an existing order.
The proposed federal approach uses concentration and relative-mass criteria. Those criteria are proposed scheduling boundaries, not recommended serving sizes or findings that a product is safe. DEA expressly states that neither it nor the Department of Health and Human Services has found below-threshold products safe to use.
For an incident tied to a particular date, obtain the filed rule and any later amendments or orders. LDH’s linked declaration says it lasts for the maximum period permitted by the Administrative Procedure Act or until a final rule is adopted, whichever comes first. It does not supply a completed effective-date entry from which this guide can responsibly calculate an expiration date.
Does the rule answer whether every “kratom” product is legal?
No. It answers which substances this particular Louisiana declaration adds. It does not, by itself, resolve the legal status of every leaf product, extract, tablet, gummy, or liquid sold under the kratom name. That question can require the product’s actual composition, the law in force on the relevant date, other state restrictions, and federal food, drug, and controlled-substance requirements.
Likewise, the absence of a name from these three entries does not establish legality. In particular, the rule should not be summarized as if “mitragynine” and “mitragynine pseudoindoxyl” were two spellings of the same compound.
Safety is a separate question. The FDA warns consumers against products containing added or enhanced 7-hydroxymitragynine, often called 7-OH. Its consumer guidance states that no 7-OH-containing drug is FDA-approved and that these products can cause serious harm. Availability in a shop or on a website is not evidence of FDA approval.
What records matter if someone reports an injury?
The first priority is appropriate medical care. For a later investigation, the useful records connect a particular product, a particular purchase, and a particular medical event. A general news report about kratom does not establish what was in a product or what caused an individual injury.
- Product identity: photographs of the package and every label panel, the exact product name, manufacturer or distributor information, lot number, and any existing certificate of analysis.
- Purchase details: receipt, order confirmation, seller’s name, purchase date, and the product description or advertising available at the time.
- Medical chronology: when the product was reportedly used, symptoms, treatment records, test results, and other substances or medications discussed with treating clinicians.
- Communications: messages with the seller or manufacturer, refund requests, and any report made to a regulator.
Do not mail, transport, or retain an unlawful substance merely to assemble evidence. Ask counsel and the appropriate authorities how any remaining material can be handled and preserved lawfully. Photographs and purchase records can be preserved without transferring the substance itself. Reports of suspected adverse events can also be made through the FDA’s reporting channels.
A scheduling decision does not decide a civil injury claim
A regulator’s decision and a product-liability claim ask different questions. A claim still requires analysis of the responsible parties, the applicable legal theory, the product and warnings, causation, and the losses supported by the evidence. Our guide to Louisiana defective-product claims explains why identifying the product and preserving the relevant records matter.
Medical bills create a further, separate question. A hospital’s financial-assistance process may be available without waiting for a liability dispute to end; our comparison of Louisiana hospital financial-assistance policies explains how to locate those requirements.
Sources and legal developments current through October 20, 2026. This guide addresses the identified rule and notices, rather than giving a product-specific determination of legality.
More primary-source guides are available in Louisiana Legal Research.